P/B
1,9
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
$4.9M
Market Cap • 10/2/2026
2022
(4 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,7
EPS
—
Market Cap
Market Cap
4,9M
EV
14,5M
EV/Revenue
11,9
EV/EBITDA
-1,7
EV/EBIT
-1,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-165,9%
Total Yield
-165,9%
Payout
0%
Retained Earnings
-52,2M
Profitability
Gross Margin
26,3%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
191,7%
Capex/Revenue
9,9%
Capex/D&A
116,3%
Capex/OCF
-1,4%
SBC/OCF
—
% PPE
5,7%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0
Quick Ratio
0
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!